Dr. Federman on Ongoing Research in Rare Bone and Soft Tissue Sarcoma

Noah Federman, MD
Published: Wednesday, Oct 28, 2015



Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles (UCLA), discusses ongoing research in rare bone and soft tissue sarcoma.

Current research at UCLA’s Jonnson Comprehensive Cancer Center is focused on patients with rare bone and soft tissue sarcoma, which generally occur in children, adolescents, and young adults, Federman says. One ongoing clinical trial is looking at imaging with PET/CT scans to more accurately diagnose and stage these diseases, as well as observe responses to therapies.

A second trial is examining the efficacy of novel targeted chemotherapy agents toward ewing sarcoma and rhabdomyosarcoma. It is hopeful that these agents will improve patient outcomes, Federman says.



Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles (UCLA), discusses ongoing research in rare bone and soft tissue sarcoma.

Current research at UCLA’s Jonnson Comprehensive Cancer Center is focused on patients with rare bone and soft tissue sarcoma, which generally occur in children, adolescents, and young adults, Federman says. One ongoing clinical trial is looking at imaging with PET/CT scans to more accurately diagnose and stage these diseases, as well as observe responses to therapies.

A second trial is examining the efficacy of novel targeted chemotherapy agents toward ewing sarcoma and rhabdomyosarcoma. It is hopeful that these agents will improve patient outcomes, Federman says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x